|
BIOMUNE SYSTEMS,
INC.'S OPTIMUNE SELECTED BY AIDS CLINICAL TRIAL GROUP FOR
ITS FIRST EVER NUTRITIONAL STUDY
Salt Lake City, UT, January 27, 1999
Biomune Systems, Inc. (NASDAQ:BIME) today announced its
wholly owned subsidiary Optim Nutrition, Inc.'s OPTIMUNE®,
which contains the Company's patented whey protein concentrate
ProMuneò, was selected as a nutritional supplement
to be studied by the AIDS Clinical Trial Group (ACTG). The
randomized, double blind, ACTG nutritional study will commence
at 10 different study sites across the United States within
the next few months. The ACTG is supported by the National
Institutes of Health (NIH) and the National Institute of
Allergy and Infectious Diseases (NIAID).
This is the first study of a nutritional supplement to be
conducted by ACTG, stated Fred Sattler, M.D., University
of Southern California Medical Center and Co-Chair of the
12-week ACTG study. The study is designed to be a comprehensive
evaluation of protein metabolism and its effect on body
composition. This is an important area of HIV/AIDS research
worldwide and we are anxious to start the study.
We are excited about the opportunity to investigate the
possible benefits of the unique amino acid profile and composition
of OPTIMUNE in people with AIDS and weight loss. This type
of high quality, high biologic value protein could play
an important nutritional role in Cachexia (Wasting), says
ACTG Study Protocol Chairman, Bruce Bistrian, M.D.,Ph.D.,
Beth Israel Deaconess Medical Center, Harvard Medical School.
According to The World Health Organization, The Centers
for Disease Control Surveillance Report 1996, wasting is
the second leading HIV/AIDS related cause of death in the
U.S., and the third leading cause of HIV/AIDS related death
worldwide.
We are pleased to have OPTIMUNE chosen as the protein supplementation
for this nutritional study with the ACTG, stated Biomune
System,s CEO, Michael G. Acton, "The development of
Optim Nutrition's ProMune and OPTIMUNE nutritional supplements
is a result of Biomune System's extensive drug and clinical
trial research. OPTIMUNE is a high biologic value, high
quality patented whey protein with more than 16 years of
research and development on its patented whey technology.
The exclusive process produces a whey product exceptionally
rich in immunoglobulins (natural antibodies) and other immune
enhancing components. Optim Nutrition President, Randy Olshen
said, "We look forward to participating in a study
with such a prestigious group of physicians, researchers
and government agencies. We hope its commencement marks
the continuance of research involving the role of nutraceuticals,
medical foods and functional foods in complementary applications.
Biomune Systems, Inc. is a biopharmaceutical research and
development company that is involved in researching the
various applications of its patented whey protein ProMune
in immune-compromised individuals and cancer research. Biomune
Systems, Inc.,s wholly owned subsidiary, Optim Nutrition,
Inc. is engaged in manufacturing, new product development
and marketing of nutraceuticals, functional foods, medical
foods and dietary supplements.
This press release may contain certain forward looking statements
about the Company's goals and anticipated future performance.
The industry in which the Company proposes to operate is
dynamic and intensely competitive and there are many factors
that could cause the forward looking statements contained
herein not to occur or the timing of their occurrence to
be delayed. With the exception of historical information,
the matters discussed in this press release are forward-looking
statements that involve substantial risks and uncertainties,
including, but not limited to, the results of ongoing studies
and trials, economic conditions, product and technology
development, production efficiencies, product demand, competitive
products and competitive environment, availability of raw
materials and critical manufacturing equipment and facilities,
and other risks identified in filings made with the Securities
and Exchange Commission
Contact: Randy Olshen at 801-466-3441 ext. 106 or, Sandy
Biggs, ext 105.
|
